CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Ixekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03942042
NCT03942042Phase 4Completed
CompareCT.gov

A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Eli Lilly and Company·interventional·Posted May 8, 2019·Updated Aug 13, 2021

In Brief

A Phase 4 clinical trial evaluating Ixekizumab for Generalized Pustular Psoriasis and Erythrodermic Psoriasis. Completed, enrolled 12 participants across 7 sites.

Detailed Summary

The reason for this study is to see if the study drug ixekizumab is safe and effective in participants with generalized pustular psoriasis and erythrodermic psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Pustular Psoriasis, Erythrodermic Psoriasis
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedMay 8, 2019
Enrollment StartJul 5, 2019
Primary CompletionJul 22, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.1 years ago

Interventions

Ixekizumabdrug

Administered SC